Tormentic Acid, a Major Component of Suspension Cells of Eriobotrya

Subscriber access provided by Milne Library, SUNY Geneseo

Article

Tormentic Acid, a Major Component of Suspension Cells of Eriobotrya japonica, Suppresses High-Fat Diet-Induced Diabetes and Hyperlipidemia by Glucose Transporter 4 and AMP-Activated Protein Kinase Phosphorylation Jin-Bin Wu, Yueh-Hsiung Kuo, Cheng-Hsiu Lin, Hui-Ya Ho, and Chun-Ching Shih J. Agric. Food Chem., Just Accepted Manuscript • DOI: 10.1021/jf503334d • Publication Date (Web): 15 Oct 2014 Downloaded from http://pubs.acs.org on October 17, 2014

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Journal of Agricultural and Food Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 46

Journal of Agricultural and Food Chemistry

1

Tormentic Acid, a Major Component of Suspension Cells of

2

Eriobotrya japonica, Suppresses High-Fat Diet-Induced Diabetes and

3

Hyperlipidemia by Glucose Transporter 4 and AMP-Activated

4

Protein Kinase Phosphorylation

5 6

Jin-Bin Wu,† Yueh-Hsiung Kuo,# Cheng-Hsiu Lin,‡ Hui-Ya Ho,§ and Chun-Ching

7

Shih║,*

8 †

9 10 11

Taichung City 40402, Taiwan #

Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources,

12

China Medical University, Taichung City 40402, Taiwan ‡

13

Department of Internal Medicine, Fong-Yuan Hospital, Department of Health,

14

Executive Yuan, Fong-Yuan District, Taichung City 42055, Taiwan §

15 16

Graduate Institute of Pharmaceutical Chemistry, China Medical University,

║,

Jen Li Biotech Co. Ltd., Yong-feng Road, Taiping City, Taichung 411, Taiwan

* Graduate Institute of Pharmaceutical Science and Technology, College of Health

17

Science, Central Taiwan University of Science and Technology, No.666, Buzih Road,

18

Beitun District, Taichung City 40601, Taiwan

19

1

ACS Paragon Plus Environment


Page 2 of 46

20

ABSTRACT:

21

acid (PTA) on diabetes and dyslipidemia in high-fat (HF)-fed mice. Feeding

22

C57BL/6J mice with a HF diet for 12 weeks induced type 2 diabetes and

23

hyperlipidemia. During the last 4 weeks, the mice were given orally PTA (at two

24

dosages) or rosiglitazone (Rosi) or water. In this study, HF-diet increases glucose,

25

triglyceride, insulin and leptin levels, while PTA effectively prevented these

26

phenomenons and ameliorated insulin resistance. PTA reduced visceral fat mass and

27

hepatic triacylglycerol contents; moverover, PTA significantly decreased both the area

28

of adipocytes and ballooning degeneration of hepatocytes. PTA caused increased

29

skeletal muscular AMP-activated protein kinase (AMPK) phosphorylation and Akt

30

phosphorylation and glucose transporter 4 (GLUT4) proteins, whereas reduced the

31

hepatic expressions of phosphenolpyruvate carboxykinase (PEPCK) and

32

glucose-6-phosphatase (G6Pase) genes. PTA enhanced skeletal muscular Akt

33

phosphorylation and increased insulin sensitivity. PTA also enhanced phospho-AMPK

34

in the liver. Therefore, it is possible that the activation of AMPK by PTA results in

35

decreasing hepatic glucose production, while increasing skeletal muscular GLUT4

36

contents, thus contributed to attenuating diabetic state. Moreover, PTA exhibits

37

anti-hyperlipidemic effect by down-regulations of the hepatic sterol regulatory

38

element binding protein-1c (SREBP-1c) and apolipoprotein C-III (apo C-III) while

It was designed to evaluate the effects and mechanism of tormentic

2


Page 3 of 46


39

increased peroxisome proliferator activated receptor (PPAR)-α expression, thus

40

resulting in decreases in blood triglycerides. Our findings demonstrated that PTA was

41

effective for the treatment of diabetes and hyperlipidemia in HF-fed mice.

42 43

KEYWORDS: tormentic acid, anti-diabetes, anti-hyperlipidemia, AMP-activated

44

protein kinase phosphorylation, glucose transporter 4

3



Page 4 of 46

45

Introduction

46

Type 2 diabetes represents greater than 90% of all diabetes cases. Insulin resistance is

47

the majority of type 2 diabetes caused by insensitivity to insulin in peripheral tissues.

48

It is predicted that the world’s population of type 2 diabetes would be reached 6.1%

49

by 2025.1 Therefore, to find the safer and less toxic substitute in the treatment of type

50

2 diabetes mellitus becomes important. Type 2 diabetes mainly reduces glucose

51

uptake.2 Type 2 diabetes is accompanied by several complications to cause a series of

52

metabolic diseases including obesity and dyslipidemia. It is known that blood glucose

53

and lipid constitutes fluctuating homeostasis. Thus, to find the good resolution of

54

glucose uptake and hepatic gluconeogenesis is an important issue in Type 2 diabetes.

55

Insulin is secreted after a meal, and followed by glucose transporter 4 (GLUT4)

56

was increased and translocated to the plasma membrane, and thus lead to glucose

57

uptake into cells, contributing to reduced blood glucose.3,4 Insulin resistance and

58

hyperglycemia was caused by problems in GLUT4 translocation and uptake.5,6 Thus,

59

it is an important issue to increase protein contents and/or translocation of GLUT4 in

60

the management of diabetes.

61

AMP-activated protein kinase (AMPK) has regulated various metabolic pathways,

62

and it is considered as an important target for the management of metabolic diseases

63

including type 2 diabetes and dyslipidemia.7,8,9 Type 2 diabetes is found dysfunctional

4


Page 5 of 46


64

in glucose and lipid metabolism, therefore AMPK modulators have been suggested to

65

be promising therapies.10

66

The plant Eriobotrya japonica Lindl. (Figure 1A) is an evergreen fruit tree and

67

belongs to Rosacease. The most used part of this plant is the dried leaf to treat

68

diabetes mellitus.11,12 It is composed of many pentacyclic triterpenes, which

69

demonstrate various pharmaceutical effects including hepato-protection13 and

70

anti-diabetes.14,15 Callus tissue culture of loquat is reported to produce large amounts

71

of triterpenes.16 We have recently shown that loquat leaf extract as well as its cell

72

suspension culture (which contains five main bioactive constituents including

73

tormentic acid (PTA), see chemical structure in Figure 1B), could improve insulin

74

sensitivity and hyperlipidemia,17,18 we think it is possible that the five constitutes act

75

synergistically (a synergistic effect is one in which the combined effect of two

76

chemicals is greater than the sum of the effect of each agent given alone) on diabetes

77

and lipid. Nevertheless, the effect of single and pure PTA of anti-diabetes and

78

anti-dyslipidemia is still not fully understood. The aerial part of Poterium ancistroides

79

Desf. contained tormentic acid and exhibited the anti-diabetic activity.19 Tormentic

80

acid has been shown to lower blood glucose in normoglycemic and glucose-induced

81

hyperglycemic rats19 and initiates insulin secretion by isolated rat islets of

82

Langerhans.20

5



Page 6 of 46

83

The mouse C57BL/6 model fed with a HF diet could induce insulin resistance,

84

obesity, hyperlipidemia, hyperinsulinemia, hyperleptinemia, and excess circulating

85

free fatty acid.21,22 Therefore, we conducted our animal study using HF diet-induced

86

diabetic and hyperlipidemic states. AMPK activity is depended on phosphorylation of

87

Thr 172 of α subunits.23 This study also examined the effect of PTA on the expression

88

or protein of genes involved in antidiabetes and lipogenesis, including GLUT4, Akt,

89

AMPK, phosphoenol pyruvate carboxykinase (PEPCK), and glucose-6-phosphatase

90

(G6Pase), sterol regulatory element binding protein-1c (SREBP-1c), peroxisome

91

proliferator-activated receptor α (PPARα) and apolipoprotein C-III (apo-CIII).

92 93

MATERIALS AND METHODS

94

Chemicals. GLUT4 was purchased from Santa Cruz Biotechnology (CA, USA),

95

phospho-AMPK from Abcam Inc (Cambridge, MA, USA), phospho-Akt, total AMPK

96

and total Akt from Cell signaling Technology, Inc. (Danver MA, USA) and BCA

97

protein assay kit from Thermo Scientific (Rockford, IL, USA) and ECL reagent kit

98

from GE Healthcare BioSciences (Buckinghamshire, UK). Secondary antibody

99

anti-rabbit were from Jackson Immuno Research, Laboratories, Inc. (Pennsylvania,

100

USA). Structural proteins GAPDH were from Santa Cruz Biotecnology (CA, USA)

101

and β-actin from Santa Cruz Biotecnology (CA, USA).

6


Page 7 of 46


102 103

Isolation of tormentic acid

104

PTA was obtained from Jen Li Biotech Co. The parts of Callus induction,

105

suspension cultures, extraction and isolation of tormentic acid from suspension cells

106

of E. japonica are shown as previously described.16,24 Briefly, sterilized seeds after

107

callus induction, subculture were cultured in a bioreactor, and the cell suspension

108

(ca.844.5g) was dried and extracted with ethanol, then concentrated to afford the

109

white powder fraction (ca.6.1g).24 The white powder (0.5g) was chromatographed on

110

a reverse silica gel column (LiChroprep RP-18, E.Merck, 40-63 µm) and then further

111

purified by preparative high performance liquid chromatography (PHPLC) to yield

112

tormentic acid.24 Tormentic acid (230.5 mg ) ： 1H- NMR(pyridine-d5): δ 1.00

113

(H-25),1.07 (H-24),1.10 (H-26),1.11 (H-30),1.26 (H-23),1.42 (H-29),1.71 (H-27),

114

3.04(H-18),3.36 (H-3α),4.09 (H-3β),5.58 (H-12). 1H- NMR(400MHz) spectra were

115

measure by Bruker AMX-400 spectrometer as previously described.24

116

Animals and experimental design.

Part 1: Oral glucose tolerance (OGTT)

117

test was performed on 12 h fasted ICR mice (n=5) but were allowed access to 0.2,

118

0.4, 0.8 g/kg tormentic acid (PTA) or an equivalent amount of vehicle (water) which

119

were given orally 30 min before an oral glucose load (1 g/kg body weight). The

120

control group was given with glucose, while the normal group was without glucose.

7



Page 8 of 46

121

Blood samples were collected from the retro-orbital sinus of fasted mice at the time of

122

the glucose administration (0) and every 30 minutes until 120 minutes after glucose

123

administration. Blood glucose level was monitored. Part 2: C57BL/6J mice (4 weeks

124

old) were obtained from the National Laboratory Animal Breeding and Research

125

Center. The mice were divided randomly into two groups after 7 days acclimation.

126

The control (CON) group (n=9) was fed a low-fat diet (Diet 12450B, Research Diets,

127

Inc., New Brunswick, NJ 08901 USA), whereas the experimental group was fed a

128

45% high-fat diet (Diet 12451, Research Diets, Inc., New Brunswick, NJ 08901 USA)

129

for 12 weeks.18,25 The compositions of the experimental diets are shown as previous

130

study described.18,25 After 8 weeks, the high-fat treated mice were randomly

131

subdivided into 4 groups (n=9) including PTA (0.06, 0.12 g/kg/day) or rosiglitazone

132

(Rosi; 1% methylcellulose 10 mg/kg body weight) (GlaxoSmithKline) or vehicle were

133

treated by oral gavage one time per day from the 9th to 12th week, while the mice

134

were still on the high-fat diet, whereas the CON and high-fat control (HF) mice were

135

treated with vehicle only. At the end, food is deprived from animal (from 10 p.m. to

136

10 a.m.). The next day, the mice were sacrificed for blood and tissue collection and

137

analysis. Livers, skeletal muscles and white adipose tissues (WATs) (including

138

epididymal, mesenteric and retroperitoneal WAT) were weighed and excised, followed

139

by immediately freezing and kept at -80 ℃ for target gene analysis. Heparin (30

8


Page 9 of 46


140

units/ml) (Sigma) were added into blood sample. Plasma samples were collected

141

within 30 min by centrifugation at 1600 × g for 15 min at 4 ℃. Plasma was obtained

142

for insulin and leptin assay.18,25

143

Measurement of body weight, body weight gain and food intake.

Body

144

weight was measured daily at the same time throughout the study. Body weight gain

145

is defined as the differences between the day and the next day. The pellet food was

146

weighed and followed by placing in food container. After 24 h, the remaining food

147

was weighed, and the difference represented the daily food intake.

148

Analysis of blood parameters.

Blood samples (0.8 mL) were collected from

149

retro-orbital sinus of fasted mice and glucose level was analyzed by the glucose

150

oxidase method (Model 1500; Sidekick Glucose Analyzer; YSI Incorporated, Yellow

151

Springs, OH, USA).18,25 Plasma triglycerides (TG), total cholesterol (TC) and free

152

fatty acids (FFA) were measured using commercial assay kits according to the

153

manufacturer’s directions (Triglycerides-E test, Cholesterol-E test and FFA-C test,

154

Wako Pure Chemical, Osaka, Japan).17,18 The levels of insulin and leptin in blood

155

were analyzed by ELISA using a commercial assay kit according to manufacturer’s

156

directions (mouse insulin ELISA kit, Sibayagi, Gunma, Japan and mouse leptin

157

ELISA kit, Morinaga, Yokohama, Japan).18,25

158

Analysis of histopathology.

Small pieces of epididymal WAT and liver tissue

9



159

were fixed with formalin (200 g/kg) neutral buffered solution and embedded in

160

paraffin. Sections (8 µm) were cut and stained with hematoxylin and eosin. For

161

microscopic examination, a microscope (Leica, DM2500) was used, and the images

162

were taken using a Leica Digital camera (DFC-425-C).18

163

Analysis of hepatic lipids.

Hepatic lipids were extracted using a previously

164

described protocol.17 For the hepatic lipid extraction, the 0.375 g liver samples were

165

homogenized with 1 mL distill water for 5 min. Finally, the dried pellet was

166

resuspended in 0.5 mL ethanol and analyzed using a triglycerides kit as used for

167

serum lipids.18

168

Page 10 of 46

Isolation of RNA and relative quantization of mRNA indicating gene

169

expression.

170

(Molecular Research Center, Inc., Cincinnati, OH) according to the manufacturer’s

171

directions. The integrity of the extracted total RNA was examined by 2% agarose gel

172

electrophoresis, and the RNA concentration was determined by the ultraviolet (UV)

173

light absorbency at 260 nm and 280 nm (Spectrophotometer U-2800A, Hitachi). Total

174

RNA (1 µg) was reverse transcribed to cDNA with 5µL Moloney murine leukemia

175

virus reverse transcriptase (Epicentre, Madison, WI, USA) as a previously described

176

protocol.17,25 The polymerase chain reaction (PCR) was performed in a final 25µL

177

containing 1U Blend Taq™ -Plus (TOYOBO, Japan), 1 µL of the RT first-strand

Total RNA from the liver tissue was isolated with a Trizol Reagent

10


Page 11 of 46


178

cDNA product, 10 µΜ of each forward (F) and reverse (R) primer, 75 mM Tris-HCl

179

(pH 8.3) containing 1 mg/L Tween 20, 2.5 mM dNTP and 2 mM MgCl2.17,18,25 The

180

primers are shown in Table 1. The products were run on 2% agarose gels and stained

181

with ethidium bromide. The relative density of the band was evaluated using

182

AlphaDigiDoc 1201 software (Alpha Innotech Co., San Leandro, CA, USA). All the

183

measured PCR products were normalized to the amount of cDNA of GAPDH in each

184

sample.17,18,25

185

Western Immunoblotting analysis.

This part is according to a previous

186

report,18,26,27 protein extractions and immunoblots for the determination of GLUT4,

187

phospho-AMPK (Thr172) and phospho-Akt (Ser 473) proteins were carried out on

188

frozen skeletal muscle and liver tissue from mice. Briefly, samples liver tissue (0.1g)

189

was homogenized with lysis buffer (pH6.4) and protease inhibitors. 40 µg of each

190

homogenate is used for SDS-PAGE and immunoblotting as a previously described

191

protocol.18,26,27 Additionally, GLUT4 were carried out on frozen skeletal muscle from

192

mice briefly described: Skeletal muscle (1 g) was powdered under liquid nitrogen and

193

homogenized for 20 s in buffer (pH 7.4). The total membrane fractions were

194

collected with buffer and centrifuged as a previously described protoco.28,29 The

195

protein contents of GLUT4, phospho-AMPK, phospho-Akt, total AMPK and total Akt

196

were detected by immunoblotting using a rabbit polyclonal antibody. The protein

11



Page 12 of 46

197

concentration in supernatant was determined with a BCA protein assay kit. The

198

membranes were blocked with 5% slim milk in Tris-buffered saline (TBS) (Amershan

199

BioSciences, Uppsala, Sweden) containing 0.05% Tween-20 (Bio Rad, CA, USA) and

200

incubated overnight at 4℃ with anti-GLUT4, anti-phospho-AMPK and

201

anti-phospho-Akt at 1:200 dilution and anti-total-AMPK and anti-total-Akt at 1:1000

202

dilution. Subsequently, the membranes were washed three times with TBS containing

203

0.05% Tween-20 and incubated with secondary antibody anti-rabbit (1:1000) for 1h.

204

Immunoreactive bands were detected with ECL reagent kit. The density blotting was

205

analyzed using Alpha Easy FCTM software (Alpha innotech corporation, Randburg,

206

SA). Structural proteins GAPDH and β-actin were obtained by stripping the

207

nitrocellulose membrane proteins of liver and skeletal muscle, respectively.18,26,27

208

Statistical Analysis.

All results are presented as the mean and standard error.

209

Statistical significance is calculated by Dunnett’s multiple range tests, using SPSS

210

software (SPSS Inc., Chicago, IL, USA).

211 212

RESULTS

213

OGTT Assay.

214 215

Administration of 0.2, 0.4 and 0.8 g/kg tormentic acid decreased

the levels of blood glucose from 30 to 120 min following a glucose-loading. Body weight and food parameters.

It was measured body weight of mice at

12


Page 13 of 46


216

the end. Feeding with a high-fat diet increased body weight and body weight gain,

217

while the 4-week average food intake of the HF group is decreased. Final body weight

218

and food intake are unchanged between the PTA-treated groups and the HF group.

219

The PTA1- and PTA2- treated groups decreased the body weight gain over 4-week

220

treatment (Table 3).

221

White Adipose Tissue Fat accumulation.

The final weights of epididymal,

222

mesenteric and retroperitoneal WAT and visceral fat of the HF group were increased.

223

Administration of PTA1, PTA2 and Rosi reduced epididymal WAT, mesenteric and

224

retroperitoneal WAT and visceral fat weights (Table 3).

225

Blood parameter, leptin, insulin and liver lipid. HF-diet increased blood

226

glucose, and administration of PTA1, PTA2 and Rosi lowered blood glucose levels

227

(Figure 2B). High-fat diets caused increases in circulating TG, FFA, leptin and insulin

228

levels. The PTA1-, PTA2- and Rosi- treated mice displayed a decreased TG, FFA,

229

leptin and insulin. The PTA2- and Rosi- treated mice decreased TC levels. HF-diet

230

increased the total lipids of liver and concentrations of triacylglycerol whereas mice

231

administrated PTA1, PTA2 and Rosi significantly decreased these phenomenon.

232

Pathological Diagnosis.

HF-induced the adipocyte hypertrophy (the average

233

area of adipocytes in the HF group and CON group is 6515.9 ± 495.1 and 2584.6 ±

234

205.8 µm2, respectively), whereas mice administrated of PTA1 (2380.9 ± 108.6 µm2)

13



235

and PTA2 (2243.2 ± 100.9 µm2) significantly lower their hypertrophy. The average

236

area of the Rosi-treated mice is 4574.4 ± 162.7 µm2 (Figure 3A). According to a

237

previous study,30 designation of histological hepatocellular ballooning findings

238

included grade 0, none; grade 1, few cells; grade 2, many cells. The ballooning

239

phenomenon in liver is visible on HF-diet (mean score: 1.7 ± 0.2). The ballooning

240

phenomenon is lower in the PTA1 (1.0 ± 0.2), PTA2 (0.7 ± 0.2) and Rosi (0.9 ± 0.2)

241

treated mice (Figure 3B).

242

Hepatic Target gene expressions.

Page 14 of 46

The mRNA levels of PEPCK, G-6Pase,

243

11beta hydroxysteroid dehydrogenase 1 (11β-HDS1), diacyl glycerol acyltransferase

244

2 (DGAT2), PPARα, SREBP1c, FAS (fatty acid synthase) and apo C-III were

245

increased in the HF group. Following treatment, the PTA1-, PTA2- and Rosi- treated

246

groups decreased the mRNA level of PEPCK, G-6Pase, DGAT2, 11β-HSD1,

247

SREBP1c, FAS and apo-C-III. The PTA1- and PTA2- treated groups increased the

248

mRNA level of PPARα (Figure 4).

249

The protein contents of phospho-AMPK (Thr172), GLUT4 and phospho-Akt

250

(Ser 473)/ total Akt in different tissues.

251

protein were decreased in the HF group, while the PTA1-, PTA2- and Rosi- treated

252

groups increased the protein contents of both hepatic and skeletal muscular

253

phospho-AMPK. HF-induced the protein contents of GLUT4 and phospho-Akt

The protein contents of phospho-AMPK

14


Page 15 of 46


254

decreased, while PTA1-, PTA2- and Rosi- treated mice increased the protein contents

255

of GLUT4 and phospho-Akt in skeletal muscule (Figure 5).

256 257

DISCUSSION

258

The present results demonstrated that PTA is effective in lowering blood glucose and

259

circulating triglyceride levels in HF-fed mice. We have previously shown that loquat

260

leaf extract as well as its cell suspension culture (contained the total contents of five

261

triterpenes were 85.35% including tormentic acid 44.30%, corosolic acid 19.50%,

262

maslinic acid 14.65%, oleanolic acid 1.60% and ursolic acid 5.30%, respectively),18

263

could improve insulin sensitivity and hyperlipidemia.17,18 Since cell suspension

264

culture contained 44.3% tormetic acid, it is possible that the five constitutes act

265

synergistically and exert more potent effect on diabetes and lipid. Nevertheless, the

266

effect of single and pure tormentic acid (PTA) on diabetes and dyslipidemia is still not

267

fully understood; therefore, we hypothesized that the present study of pure PTA could

268

exhibit an effect in glucose control and lipid metabolism. Indeed, treatment with PTA

269

displayed hypoglycemic and hypolipidemic effect.

270

C57BL/6J mice fed with a high-fat diet is a mouse model to induce type 2

271

diabetes.31 HF- induced model had also elevated levels of triglycerides.31 Therefore,

272

this model was used in the present study for investigating PTA’s effects on diabetes

15



Page 16 of 46

273

and dyslipidemia. In the present study, feeding C57BL/6J mice with HF diet induced

274

hyperglycemia, obesity, hyperinsulinemia, hypertriglyceridemia, hyperleptinemia and

275

excess circulating free fatty acid, consistent with earlier observations.31 Following

276

treatment with PTA, blood glucose levels, circulating triglycerides and visceral fat

277

mass were lowered as well as a reduction in free fatty acid and improved insulin

278

resistance.

279

One of the difficulties in pursuing the mechanism of action of this compound is

280

its limited availability, although at present PTA could be produced a great quantity.

281

Therefore, PTA was firstly administered at the concentration of 0.2, 0.4, 08 g/kg in

282

OGTT test by ICR mice. It was found PTA could lower blood glucose levels. Then,

283

PTA was administered at the concentration of 0.06, 0.12 g/kg in chronic HF-fed mice.

284

Based on the few amounts of PTA and the duration of 4-week chronic treatment of

285

experimental design and tormentic acid at dosage of 30 mg/kg exerting

286

antihyperglycemic effect but did not act in rats with severe diabetes induced by an

287

injection of streptozotocin [19,20], the concentration of PTA is lowered to 0.06, 0.12

288

g/kg (duplicated or four times) in HF-fed mice; the daily dosage is expected to an

289

accumulative effect and long-lasting in effectiveness.

290

The primary aim is to investigate the anti-diabetic mechanism of PTA, and we

291

evaluate the GLUT4 protein content in the skeletal muscle. The present study showed

16


Page 17 of 46


292

that PTA2 caused markedly increases GLUT4 protein and PTA1 displayed similar

293

GLUT4 levels as Rosi, which is an anti-diabetic agent and directly targets insulin

294

resistance and increases peripheral glucose uptake (GLUT4) lead to improved

295

glycemic control.32 These findings at the first time revealed that PTA caused increased

296

GLUT4 proteins and directly with relation to exhibit anti-diabetes. Thus, PTA

297

displayed a very marked enhancement of GLUT4 accompanied by ameliorated insulin

298

resistance.

299

There are two pathways in regulated GLUT4 translocation including the insulin

300

signaling (those involving phosphatidyl inositol 3’ kinase (PI3K)/Akt) and the AMPK

301

pathway.33 To monitor the mechanism of enhanced GLUT4 by PTA, we evaluated its

302

effects on the phosphorylation of Akt in the skeletal muscle. The results demonstrated

303

that PTA had a significant increased effect on skeletal muscular phosphorylation of

304

Akt, suggesting that PTA increased muscular GLUT4 contents is likely to be partly

305

mediated by Akt phosphorylation; moreover, PTA enhanced Akt phosphorylation and

306

increased insulin sensitivity.

307

Further, it was evaluated that PTA acts on phosphorylation of AMPK to the same

308

effect that people who exercise or take antidiabetic agents such as AICAR and

309

metformin34,35 and rosiglitazone could activate AMPK. TZDs exhibit as an AMPK

310

activator but different from metformin, and reduces liver fat accumulation and

17



Page 18 of 46

311

ameliorated insulin resistance due to its effect on plasma adipocytokine (including

312

adiponectin and leptin) and more AMPK activation.36,37 Indeed, PTA increases

313

skeletal muscular phosphorylation of AMPK, suggesting that it is possibly partly

314

responsible for increased GLUT4 translocation. Further study on phosphorylation of

315

AS160 is needed.

316

The liver is the organ responsible for the majority of hepatic gluconeogenesis.38 A

317

number of hormones regulate a set of genes (including PEPCK and G-6Pase) in the

318

liver that modulates the rate of glucose synthesis. PEPCK is a rate-controlling step of

319

gluconeogenesis in animals, and G-6Pase plays a vital role in glucose homeostasis.39

320

Over expression of PEPCK enzyme in mice results in symptoms of type 2 diabetes.

321

The hepatic G-6Pase activities of diabetic animals were increased.40 PTA treatment

322

reduced the expressions of PEPCK and G-6Pase. Therefore, antidiabetic effect of PTA

323

is due to down-regulation of PEPCK and G-6Pase. Furthermore, PEPCK is controlled

324

by hormonal mechanisms including 11β-HSD1. 11β-HSD1 knockout mice fed with a

325

HF diet are protected from developing insulin resistance.41,18 Therefore, compounds

326

that down-regulate 11β-HSD1 might contribute to antidiabetic activities.18 Besides

327

PEPCK and G-6Pase, PTA decreased hepatic 11β-HSD1 expressions also lead to

328

enhanced insulin sensitivity.

329

AMPK activation is beneficial in the management of type 2 diabetes.42 Metformin

18


Page 19 of 46


330

is a medication for the treatment of type 2 diabetes by the reason of increased skeletal

331

muscular glucose uptake whereas reduced gluconeogenesis in the liver.20 HF-induced

332

reduced phospho- AMPK in the liver, with increased in PTA- and Rosi- treated

333

groups, indicating improved hyperglycemia by AMPK activation. Besides increasing

334

muscular glucose uptake (GLUT4), PTA is likely to reduce hepatic glucose

335

production by down-regulations of PEPCK and G-6Pase via AMPK.

336

To monitor the mechanism of PTA on anti-hyperlipidemia, we found that PTA

337

increased PPARα expressions. PPARα ligands (such as fibrates) have been shown to

338

reduce the expression of the apo C-III gene,43 thus resulting in lowering fat values in

339

the blood and liver and exhibiting hypotriglyceridemic effect. We also measured

340

DGAT2 expressions. DGAT2 catalyzes the final step in the synthesis of

341

triglycerides.44,18 It was found that PTA decreased circulating TG levels and this may

342

be associated with decreased DGAT2 expressions. Previous study showed that leptin

343

activated AMPK.45 It is possible that PTA directly caused AMPK phosphorylation or

344

alter leptin secretion by PTA inducing AMPK activation. Blood leptin level is

345

markedly reduced in PTA-treated mice. It is consistent with its reduced fat mass.46

346

PTA significantly reduced SREBP1c, a key transcription factor controlling de novo

347

lipogenesis.47 Moreover, PTA suppressed the expression of FAS, which is a key

348

enzyme in fatty acid synthesis. The glucose-induced SREBP1c and FAS mRNA levels

19



349

were also down-regulated by AMPK.48 The AMPK activator metformin has been

350

shown to down-regulate the FAS expression via AMPK activation.7 Therefore, it is

351

possible that PTA down-regulated these genes through AMPK activation.

Page 20 of 46

352

The evidence for morphological analysis comes from the finding that treatment

353

with PTA1 and PTA2 decreased the hypertrophy of adipocytes. The liver is a major

354

organ to metabolize fat. The level of circulating TG is fluctuating,49 it is possible that

355

PTA caused fat moving from adipose to liver tissue by increasing hepatic lipid

356

catabolism thus resulted in decreased the size of adipocytes and liver lipid droplets is

357

almost absent.

358

In conclusion, this study demonstrated that PTA effectively lowers hyperglycemia

359

and hypertriglycemia in HF-fed mice. PTA improves glycemic control primarily via

360

increased skeletal muscular GLUT4 proteins to elevate glucose uptake, whereas

361

suppressed hepatic glucose production (down regulations of PEPCK and G-6Pase).

362

PTA enhanced AMPK phosphorylation both in skeletal muscle and liver. PTA

363

enhanced skeletal muscular Akt phosphorylation and increased insulin sensitivity.

364

PTA increased hepatic fatty acid oxidation (PPARα), while suppressed lipogenic

365

enzyme expression (including SREBP1c and FAS), thus contributing to lowering

366

triglyceride levels. Therefore, tormentic acid is effective on type 2 diabetes and

367

hyperlipidemia in HF-fed mice.

20


Page 21 of 46


368 AUTHOR INFORMATION

369

370

Corresponding Author

371

*Phone:+886-4-22391647 ext. 3978. Fax: +886-4-22394256. E-mail:

372

[email protected] Mail: Graduate Institute of Pharmaceutical Science and

373

Technology, College of Health Science, Central Taiwan University of Science and

374

Technology, No.666, Buzih Road, Beitun District, Taichung City 40601, Taiwan

375

Notes

376

The authors have declared that there is no conflict of interest.

377 378

ACKNOWLEDGEMENTS

379

Financial support for this study was partly provided by CTU103-A-1 form the Central

380

Taiwan University of Science and Technology.

381 382

ABBREVIATIONS USED

383

AMPK, AMP-activated protein kinase; apo C-III, apolipoprotein C-III; BAT, brown

384

adipose tissue; 11β-HSD1, 11beta hydroxysteroid dehydroxygenase; CON, control;

385

DGAT, acyl-coenzyme A: diacylglycerol acyltransferase; FAS, fatty acid synthase;

386

FFA, free fatty acid; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; G6Pase,

21



Page 22 of 46

387

glucose-6-phosphatase; GLUT4, glucose transporter 4; HF, high-fat control; OGTT,

388

oral glucose tolerance test; PEPCK, phosphenolpyruvate carboxykinase; PPARα,

389

peroxisome proliferator-activated receptor α; PTA, tormentic acid; Rosi, rosiglitazone;

390

RT-PCR, reverse transcription-polymerase chain reaction; SREBP-1c, sterol

391

regulatory element binding protein 1c; TC, total cholesterol; TG, triglyceride; WATs,

392

white adipose tissues

393 394 395 396 397

REFERENCES (1)

Stumvoll, M.; Goldstein, B.J.; Van Haeften, T.W. Type 2 diabetes: principles of

pathogenesis and therapy. Lancet 2005, 365, 1333−1346. (2)

Basu, A.; Caumo, A.; Bettini, F. et al. Impaired basal glucose effectiveness in

398

NIDDM; contribution of defects in glucose disappearance and production, measured

399

using an optimized minimal model independent protocol. Diabetes 1997, 46,

400

421−432.

401

(3)

Minokoshi, Y.; Kahn, C. R.; Kahn, B. B. Tissue-specific ablation of the GLUT4

402

glucose transporter or the insulin receptor challenges assumptions about insulin action

403

and glucose homeostasis. J. Biol. Chem. 2003, 278(36), 33609−33612.

404 405

(4)

Joost, H. G.; Bell, G. I.; Best, J. D.; Birnbaum, M. J.; Charron, M. J.; Chen, Y.

T.; Dieg, H.; James, D. E.; Lodish, H. J.; Moley, K. H.; Moly, J. F.; Mueckler, M.;

22


Page 23 of 46


406

Rogers, S.; Schurmann, A.; Seino, S.; Thotens. B. Nomenclature of the

407

GLUT4/SLC2A family of sugar/phylol transport facilitators. Am. J. Physiol.

408

Endocrinol. Metab. 2002, 282, 974−976.

409 410 411

(5)

Watson, R.T.; Pessin, J.E. Intracellular organization of insulin signaling and

GLUT4 translocation. Recent Prog. Horm. Res. 2001, 56, 175−193. (6)

Sujatha, S.; Anand, S.; Scangeetha, K. N.; Shilpa, K.; Lakshmi, J.;

412

Balakrishnan, A.; Lakshmi, B. S. Biological evaluation of

413

(3b)-STIGMAST-5-EN-3-OL as potent anti-diabetic agent in regulating glucose

414

transport using in vitro model. Int. J. Diabetes Mellit. 2010, 2, 101−109.

415

(7)

Zhou, G.; Myers, R.; Li, Y.; Chen, T.; Shen, X.; Fenyk-Melody, J.; Wu, M.;

416

Ventre, J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M. E.; Goodyear, L. J.; Moller,

417

D. E. Role of AMP-activated protein kinase in mechanism of metformin action. J.

418

Clin. Invest. 2001, 108(8), 1167−1174.

419

(8)

Foretz, M.; Taleux, N.; Guigas, B.; Horman, S.; Beauloye, C.; Andreelli, F. et

420

al.. Regulation of energy metabolism by AMPK: a novel therapeutic approach for the

421

treatment of metabolic and cardiovascular diseases. Medicine Science (Paris) 2006,

422

22, 381−383.

423 424

(9)

B. Viollet, L, Lantier, J. Devin-Leclerc, S. Hebrard, C. Amouyal, R. Mounier,

M. Foretz, and F. Andreelli. Targeting the AMPK pathway for the treatment of Type 2

23



425 426 427 428

Page 24 of 46

diabetes. Front. Biosci. (Landmark Ed). 2009, 14, 3380−3400. (10)

Musi, N. AMP-activated protein kinase and type 2 diabetes. Curr. Med. Chem.

2006, 13(5), 583−589. (11)

Noreen, W.; Wadood, A.; Hidayat, H. K.; Wahid, S. A. Effect of Eriobotrya

429

japonica on blood glucose levels of normal and alloxan-diabetic rabbits. Planta Med.

430

1988, 54, 196−199.

431 432 433 434 435 436 437

(12)

Tommasi, N. D.; Shimone, F. D.; Pizza, C. Constituents of Eriobotrya

japonica: a study of their antiviral properties. J. Nat. Prod. 1992, 55, 1067−1073. (13)

Liu, J. Oleanolic acid and ursolic acid: research perspectives. J.

Ethnopharmacol. 2005, 100, 92−94. (14)

Ivorra, M. D.; Paya, M.; Villar, A. Hypoglycemic and insulin release effects of

tormentic acid: a new hypoglycemic natural product. Planta Med. 1988, 54, 282−285. (15)

Wen, X.; Sun, H.; Liu, J.; Wu, G.; Zhang, L.; Wu, X.; Ni, P. Pentacyclic

438

triterpenes. Part 1: The first examples of naturally occurring pentacyclic triterpenes as

439

a new class of inhibitors of glycogen phosphorylases. Bioorg. Med. Chem. Lett. 2005,

440

15, 4944−4948.

441

(16)

Taniguchi, S.; Imayoshi, Y.; Kobayashi, E.; Takamatsu, Y.; Ito, H.; Hatano, T.;

442

Sakagami, H.; Tokuda, H.; Nishino, H.; Sugita, D.; Shimura, S.; Yoshida, T.

443

Production of bioactive triterpenes by Eriobotrya japonica calli. Phytochem. 2002,

24


Page 25 of 46


444 445

59, 315−323. (17)

Shih, C. C.; Lin, C. H.,; Wu, J. B. Eriobotrya japonica improves

446

hyperlipidaemia and reverses insulin resistance in high-fat-fed mice. Phytother. Res.

447

2010, 24(12), 1769−1780.

448

(18)

Shih, C. C.; Ciou, J. L.; Lin, C. H.; Wu, J. B.; Ho, H. Y. Cell suspension

449

culture of Eriobotrya japonica regulates the diabetic and hyperlipidemic signs of

450

high-fat-fed mice. Molecules 2013, 18(3), 2726−2753.

451 452 453 454 455

(19)

Villar, A.; Payẚ, M.; Hortiguela, M.D.; Cortes, D. Tormentic acid, a new

hypoglycemic agent from Poterium ancistroides. Planta Med. 1986, 52, 43-45. (20)

Ivorra, M. D.; Payẚ, M.; Villar, A. Effect of tormentic acid on insulin secretion

in isolated rat islets of Langerhans. Phytother. Res. 1989, 3(4), 145−147. (21)

Harte, R. A.; Kirk, E. A.; Rosenfeld, M. E.; LeBoeuf, R. C. Initiation of

456

hyperinsulinemia and hyperleptinemia is diet dependent in C57BL/6 mice. Horm.

457

Metab. Res.1999, 31, 570−575.

458 459 460

(22) Arner, P. Insulin resistance in type 2 diabetes: role of fatty acid. Diabetes Metab. Res. Rev. 2002, 18, S5−S9. (23)

Shen, Q. W.; Jones, C. S.; Kalchayanand, N.; Zhu, M. J.; Du, M. J. Effect of

461

dietary alpha-lipoic acid on growth, body composition, muscle pH, and

462

AMP-activated protein kinase phosphorylation in mice. J. Anim. Sci. 2005, 83,

25



463 464

Page 26 of 46

2611−2617. (24)

Chang, C. T.; Huang, S. S.; Lin, S. S.; Amagaya, S.; Ho, H. Y.; Hou, W. C.;

465

Shie, P. H.; Wu, J. B.; Huang, G. J. Anti-inflammatory activities of tormentic acid

466

from suspension cells of Eriobotrya Japonica ex vivo and in vivo. Food Chem. 2011,

467

127, 1131−1137.

468

(25)

Shih, C. C.; Lin, C. H.; Lin, W. L. Effects of Momordica charantia on insulin

469

resistance and visceral obesity in mice on high-fat diet. Diabetes Res. Clin. Pract.

470

2008, 81(2), 134−143.

471

(26)

472

hypolipidemic effects of hawthorn by assessment of gluconeogenesis and lipogenesis

473

related genes and AMP-activated protein kinase phosphorylation. Evid-Based Compl

474

Alt Med 2013; 2013, 597067.

475

(27)

476

ameliorates insulin resistance and dyslipidemia with altered hepatic glucose

477

production and fatty acid synthesis and AMPK phosphorylation in high-fat-fed mice.

478

Phytother Res 2014; 28(3), 363−371.

479

(28)

480

translocation of glucose transporters in rat hindlimb muscles. FEBS Lett. 1987,

481

224(1), 224−230.

Shih, C. C.; Lin, C. H.; Lin, Y. J.; Wu, J. B. Validation of the antidiabetic and

Shih, C. C.; Shlau, M. T.; Lin, C. H.; Wu, J. B. Momordica charantia

Klip, A.; Ramlal, T.; Young, D. A.; Holloszy, J. O. Insulin-induced

26


Page 27 of 46


482

(29)

483

insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats. J

484

Ethnopharmacol, 2009, 123(1), 82−90.

485

(30)

486

of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005,

487

41, 1313−1321.

488

(31)

Shih, C. C.; Lin, C. H.; Lin, W. L.; Wu, J. B. Momordica charantia extract on

Kleiner, D. E.; Brunt, E. M.; Van Natta, M.; Sanyal, A. J. Design and validation

Petro, A. E.; Cotter, J.; Cooper, D. A.; Peters, J. C.; Surwit, S. J.; Surwit, R. S.

489

Fat, carbohydrate and calories in the development of diabetes and obesity in the

490

C57BL/6J mouse. Metabolism 2004, 53, 454−457.

491

(32)

Martinez, L.; Berenguer, M.; Bruce, M. C.; Le Marchand-Brustel, Y.; Govers,

492

R. Rosiglitazone increases cell surface GLUT4 levels in 3T3-L1 adipocytes through

493

an anhancement of endosomal recycling. Biochem Pharmacol 2010, 79(9),

494

1300−1309.

495 496 497

(33)

Huang, S.; Czech, M.P. The GLUT4 glucose transporter. Cell Metab. 2007, 5,

237−252. (34)

Iglesias, M. A.; Ye, J. M.; Frangioudakis, G.; Saha, A. K.; Tomas, E.;

498

Ruderman, N. B.; Cooney, G. J.; Kraegen, E. W. AICAR administration causes an

499

apparent enhancement of muscle and liver action in insulin-resistant high-fat-fed rats.

500

Diabetes 2002, 51, 2886−2894.

27



501

(35)

Ye, J. M.; Ruderman, N. B.; Kraegen, E. W. AMP-activated protein kinase and

502

malonyl-CoA: Targets for treating insulin resistance? Drug Discovery Today:

503

Therapeutic Strategies 2005, 2(2), 157−163.

504

(36)

Fryer, L. G.; Parbu-Patel, A.; Patel, A. The anti-diabetic drugs rosiglitazone

505

and metformin stimulate AMP-activated protein kinase through distinct signaling

506

pathways. J. Biol. Chem. 2002, 277, 25226−25232.

507

(37)

Ahmed, M. H.; Byrne, C. D. Modulation of sterol regulatiry element binding

508

proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease

509

(NAFLD). Drug Discovery Today 2007, 12(17−18), 740−747.

510

(38)

Kurukulasuriya, R.; Link, J. T.; Madar, D. J.; et al.. Prospects for

511

pharmacologic inhibition of hepatic glucose production. Curr. Med. Chem. 2003,

512

10(2), 99−121.

513

(39)

Page 28 of 46

Guignot, L.; Mithieux, G. Mechanisms by which insulin, associated or not

514

with glucose, may inhibit hepatic glucose production in the rat. Am. J. Physiol. 1999,

515

227( 6), Pt 1, E984−989.

516

(40)

Berg, J. M.; Tymoczko, J. L.; Stryer. L. Glycolysis and glyconeogenesis. In:

517

Berg JM, Tymoczko JL (Eds.), Stryer Biochemistry. WH Freeman and Company, New

518

York, pp. 425−464, 2001.

519

(41)

Koeilevtsev, Y.; Holmes, M. C.; Burchell, A.; Houston, P. M.; Schmll, D.;

28


Page 29 of 46


520

Jamieson, P.; Best, R.; Brown, R.; Edwards, C. R.W.; Seckl, J. R.; Mullins, J. J.

521

11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated

522

glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress.

523

Proc. Natl. Acad. Sci., U. S. A. 1997, 94, 14924−14929.

524

(42)

Mackenzie, R. W.; Elliot, B. T. Akt/PKB activation and insulin signaling: a

525

novel insulin signaling pathway in the treatment of type 2 diabetes. Diabetes Metab.

526

Syndr. Obes. 2014, 7, 55−64.

527

(43)

Staels, B.; Dallongeville, J.; Auwerx, K.; Schoonjans, K.; Leitersdorf, E.;

528

Fruchart, J.-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism.

529

Circulation 1998, 98, 2088−2093.

530

(44)

Cases, S.; Stone, S. J.; Zhou, P.; Yen, E.; Tow, B.; Lardizabal, K. D.; Voelker,

531

T.; Farese Jr, R. V. Cloning of DGAT2, a second mammalian diacylglycerol

532

acyltransferase, and related family members. J. Biol. Chem. 2001, 276, 38870−38876.

533

(45)

Minokoshi, Y.; Kim, Y.-B.; Peroni, O. D.; Fryer, L. G. D.; Muller, C.; Carling.

534

D.; Kahn, B. B. Leptin stimulates fattyacid oxidation by activating AMP-activated

535

protein kinase. Nature (Lond.) 2002, 415, 339−343.

536 537 538

(46)

Myers, M. G.; Cowley, M. A.; Mȕnzberg, H. Mechanism of leptin action and

leptin resistance. Annu Rev Physiol 2008, 70, 537−556. (47)

Moon, Y. A., Hammer, R. E., Horton, J. D. Deletion of ELOVL5 leads to fatty

29



539 540

Page 30 of 46

liver through activation of SREBP-1c in mice. J. Lipid Res. 2008, 50, 412-423. (48)

Foretz, M.; Carling, D.; Guichard, C.; Ferre, P.; Foufelle, F. AMP-activated

541

protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in

542

rat hepatocytes. J. Biol. Chem. 1998, 273, 14767-14771.

543 544

(49)

Bourgeois, F.; Alexiu, A.; Lemonnier, D. Dietary-induced obesity: effect of

dietary fats on adipose tissue cellularity in mice. Br. J. Nutr. 1983, 49, 17−26.

545

30


Page 31 of 46


546

Table 1. Primers used in this study Gene

Accession

Forward primer and reverse primer

numbers

PCR

Annealing

product temperature ( (bp)

℃)

330

52

350

50

300

50

149

50

352

55

219

50

240

50

Liver PEPCK

NM_011044. F: CTACAACTTCGGCAAATACC 2

G6Pase

R: TCCAGATACCTGTCGATCTC

NM_008061. F: GAACAACTAAAGCCTCTGAAAC R: TTGCTCGATACATAAAACACTC 3

11β-HSD1 NM_008288. F:AAGCAGAGCAATGGCAGCAT 2 DGAT2

NM_026384. F: AGTGGCAATGCTATCATCATCGT 3

PPARα

R: GAGCAATCATAGGCTGGGTCA

R: AAGGAATAAGTGGGAACCAGATCA

NM_011144 F: ACCTCTGTTCATGTCAGACC R: ATAACCACAGACCAACCAAG

SREBP1c NM_011480 F: GGCTGTTGTCTACCATAAGC R: AGGAAGAAACGTGTCAAGAA FAS

NM_007988 F: TGGAAAGATAACTGGGTGAC R: TGCTGTCGTCTGTAGTCTTG

31



apo C-III NM_023114. F: CAGTTTTATCCCTAGAAGCA 3 GAPDH

Page 32 of 46

349

47

99

55

R: TCTCACGACTCAATAGCTG

NM_031144 F: TGTGTCCGTCGTGGATCTGA R: CCTGCTTCACCACCTTCTTGA

547 548

32


Page 33 of 46


549

Table 2. Absolute tissue weight, food intake, liver lipids, and blood profiles Parameter

CON

HF

HF+PTA1

HF+PTA2

HF+Rosi

0.06a

0.12a

0.01a

1.074 ± 0.154*

Absolute tissue weight (g)

EWAT

0.598 ± 0.021

1.629 ± 0.169### 1.042 ± 0.089*

0.945 ± 0.079**

RWAT

0.168 ± 0.011

0.715 ± 0.063### 0.490 ± 0.022**

0.418 ± 0.046*** 0.472 ± 0.059**

MWAT

0.288 ± 0.016

0.518 ± 0.070### 0.414 ± 0.032

0.345 ±0.038*

0.233 ± 0.034**

Visceral fat

0.766 ± 0.028

2.344 ± 0.199### 1.532 ± 0.108*

1.363 ± 0.122**

1.546 ± 0.160*

BAT

0.146 ± 0.020

0.187 ± 0.023

0.145 ± 0.020

0.125 ± 0.009*

0.156 ± 0.034

Liver (g)

0.984 ± 0.057

1.177 ± 0.107

0.927 ± 0.038

0.913 ± 0.035

0.954 ± 0.037

Spleen

0.062 ± 0.004

0.077 ± 0.004

0.078 ± 0.004

0.072 ± 0.003

0.077 ± 0.053

Final body

24.04 ± 0.33

31.91 ± 1.95### 29.43 ± 1.05

29.17± 0.80

31.85 ± 1.75

0.21 ± 0.32

2.56 ± 0.39###

0.88 ± 0.29**

0.84 ± 0.38**

2.58 ± 0.31

2.21 ± 0.03

1.84 ± 0.06###

1.71 ± 0.04

1.69 ± 0.03

1.83 ± 0.04

weight (g)

weight (g)

Body weight

gain (g)

food intake

(g/day/mouse)

Liver lipids

33



Page 34 of 46

total lipid (mg/g) 55.2 ± 5.1

98.7 ± 6.4###

80.1 ± 4.6*

68.2 ± 5.9**

74.7 ± 5.7**

Triacylglycerol

31.5 ± 4.2

68.5 ± 7.1###

51.7 ± 5.1*

35.2 ± 4.9***

43.8 ± 4.7***

FFA (meq/L)

1.63 ± 0.14

2.75 ± 0.42#

2.15 ± 0.35*

1.88 ± 0.29 *

1.85 ± 0.28*

TC (mg/dL)

87.7 ± 5.7

188.5 ± 10.2### 167.0 ± 6.1

153.7 ± 6.9*

140.7 ± 14.1*

Leptin (μg/mL)

1.523 ± 0.072

3.124 ± 0.065### 2.345 ± 0.092*** 1.780 ± 0.094*** 2.151 ± 0.099***

(µmol/g)

Blood profiles

Insulin (μU/mL) 31.3 ± 5.9

162.6 ±16.5###

101.7 ± 15.2*

73.9 ± 11.8**

56.4 ± 13.8**

550

All values are means ± S.E. (n=9). # p < 0.05, ## p < 0.01, ### p< 0.001 compared with

551

the control (CON) group; * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the

552

high-fat + vehicle (distilled water) (HF) group. Tormentic acid (PTA) (PTA1: 0.06 and

553

PTA2: 0.12 g/kg bodyweight); Rosi: rosiglitazone (0.01 g/kg body weight). BAT,

554

brown adipose tissue; RWAT, retroperioneal white adipose tissue; MWAT, mesenteric

555

white adipose tissue; Visceral fat was defined as the sum of epididymal and

556

retroperioneal WAT. FFA, plasma free fatty acid; TC, total cholesterol; TG,

557

triglyceride. aDose (g/kg/day)

558

34


Page 35 of 46


559

1A

560 561

1B

562

563 564

Figure 1. (A). The plant Eriobotrya japonica Lindl. (B). structure of tormentic acid

565

(PTA).

566 35



567

Page 36 of 46

2A

###

200

Glucose (mg/dl)

Normal Control Tormentic acid (0.2 g/kg) Tormentic acid (0.4 g/kg) Tormentic acid (0.8 g/kg) ### ###

*** *** ***

160

###

* *** *** ***

120

* *** *** ***

* *** ***

80

0

30

60

90

120

min

568 569 570

2B

36


Page 37 of 46


###

Glucose levels (mg/dL)

150

125

**

100

***

***

75

50

Control

HF

HF+PTA1 HF+PTA2 0.06 0.12

HF+Rosi 0.01 (g/kg/day)

571 572

2C

Triglyceride levels (mg/dL)

160

140 ### 120

*

100

***

**

80

60

40

Control

HF

HF+PTA1 HF+PTA2 0.12 0.06

HF+Rosi 0.01 (g/kg/day)

573 37



Page 38 of 46

574 575

Figure 2. (A). Effects of tormentic acid on oral glucose tolerance test (OGTT) in

576

normal mice. Animals in all groups received oral glucose 30 minutes after tormentic

577

acid administration. Blood samples were collected and centrifuged at 3000 rpm for 10

578

minutes. Each point is the mean ± S.E. of 5 separate mice. ### p < 0.001 compared

579

with the control (CON) group; * p < 0.05, *** p < 0.001 was significantly different

580

compared with the control group in the same time by ANOVA. (B)~ (C) Effects of

581

tormentic acid (PTA) on (B). blood glucose levels and (C) circulating triglyceride

582

levels at week 12. Mice were fed with 45% high-fat diet (HF) or low-fat diet (CON)

583

for 12 weeks. After 8 weeks, the HF mice were treated with vehicle, or tormentic acid

584

(PTA), or rosiglitazone (Rosi) accompanied with HF diet for 4 weeks. All values are

585

means ± S.E. (n=9). # p < 0.05, ## p < 0.01, ### p < 0.001 compared with the control

586

(CON) group; * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the high-fat +

587

vehicle (distilled water) (HF) group by ANOVA. Tormentic acid (PTA1: 0.06 and

588

PTA2: 0.12 g/kg bodyweight); Rosi: rosiglitazone (0.01 g/kg body weight). WAT,

589

white adipose tissue; Epididymal WAT+ Retroperitoneal WAT, visceral fat.

590

38


Page 39 of 46


591

3A

592

CON

HF

HF+PTA1

HF+PTA2

593 594

595 596

HF+Rosi

597 598

39



599

3B

600

CON

Page 40 of 46

HF

601 602

HF+PTA1

HF+PTA2

603 604

HF+Rosi

605 606

Figure 3. Effects of tormentic acid (PTA) on epididymal WAT and liver tissue

607

morphology in the low-fat (CON), high-fat (HF), HF + PTA1, HF + PTA2, or HF +

608

Rosi groups. Pictures of hematoxylin and eosin-stained sections of (a) mean area of

40


Page 41 of 46


609

adipocytes (µm2) for epididymal WAT (Magnification: 10 (ocular) × 20 (object lens)

610

from mice fed with TA. White adipose tissue (named adipocytes) is polyhedral by

611

H&E stain, and the appearance displayed the string-like cytosol being surrounded by

612

a vacuole. Because the cytosol is embedded in paraffin as immersed in lipid solvents,

613

and all the fats were finally removed. It was carefully observed unobvious nucleus (N)

614

in the other side of cells; and (B). liver tissue (Magnification: 10 (ocular) × 20 (object

615

lens)) from mice fed with PTA. The high-fat diet induced the hepatic ballooning

616

degeneration in the HF group as compared with the CON group. The ballooning

617

degeneration is a form of liver parenchymal cell death and the nucleolus was

618

squeezed into the other side named balloon (as the arrow indicated). This may be due

619

to the heap of glycogen in the nucleus. High-fat diet induced obesity and insulin

620

resistance. Insulin levels affected the storage of hepatic glycogen. Treatment with

621

PTA1 and PTA2 significantly decreased the degree of ballooning degeneration. Each

622

presented is typical and representative of nine mice. Tormentic acid (PTA1: 0.06 and

623

PTA2: 0.12 g/kg bodyweight); Rosi: rosiglitazone (0.01 g/kg body weight).

41



Page 42 of 46

624

625

626

Figure 4. Semiquantative RT-PCR analysis on PEPCK, G-6Pase, 11β-HSD1, DGAT2,

627

PPARα, SREBP1c, FAS and apo C-III mRNA expression in liver tissue of the mice by

628

oral gavage extracts of tormentic acid (PTA) for 4 weeks. All values are means ± S.E.

629

(n=9). # p < 0.05, ### p < 0.001 compared with the control (CON) group; * p < 0.05,

630

** p < 0.01, *** p < 0.001 compared with the high-fat + vehicle (distilled water) (HF)

42


Page 43 of 46


631

group. Tormentic acid (PTA) (PTA1: 0.06 and PTA2: 0.12 g/kg bodyweight); Rosi:

632

rosiglitazone (0.01 g/kg body weight). Total RNA (1µg) isolated from tissue was

633

reverse transcripted by MMLV-RT, 10µL of RT products were used as templates for

634

PCR. Signals were quantitated by image analysis; each value was normalized by

635

GAPDH.

43



Page 44 of 46

636

637 638

Figure 5. The protein contents of GLUT4 in skeletal muscle, the ratio of

639

phospho-AMPK (Thr172) to total AMPK in liver tissue and skeletal muscle, and 44


Page 45 of 46


640

quantified results for the phosphorylation status of Akt (p-Akt normalized to total Akt

641

(pAkt / Akt)) in skeletal muscle of the mice by oral gavage tormentic acid (PTA) for 4

642

weeks. Protein was separated by 12% SDS-PAGE detected by Western blot. All

643

values are means ± S.E. (n=9). # p < 0.05, ## p < 0.01 compared with the control (CON)

644

group; * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the high-fat + vehicle

645

(HF) group. Tormentic acid (PTA) (PTA1: 0.06 and PTA2: 0.12 g/kg bodyweight);

646

Rosi: rosiglitazone (0.01 g/kg body weight).

45



Page 46 of 46

Tormentic acid Suppression of diabetes and hyperlipidemia

C57BL/6J+ HF diet

Activation of AMPK Decreases in gluconeogenesis (PEPCK, G6Pase) and fatty acid synthesis (SREBP1c, FAS) Regulation of leptin secretion and increased in fatty acid oxidation (PPARα) Activation of AMPK Increased in glucose uptake (GLUT4)


Tormentic Acid, a Major Component of Suspension Cells of Eriobotrya

Recommend Documents